Tiziana Life Sciences chief medical officer Matthew Davis joins Proactive's Natalie Stoberman to share the latest results from its intranasal foralumab study that's been published in Proceedings of the National Academy of Sciences (PNAS).
Davis says the results show how intranasal foralumab has had similar immune gene expression effects in COVID patients, MS patients and in heathy volunteers that were included in the study. From this study, Davis adds that intranasal foralumab could have a wider opportunity as a treatment for other inflammatory human diseases.
Proactive US
+1 347-449-0879
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.95 |
| Daily Change: | -0.07 -3.47 |
| Daily Volume: | 405,399 |
| Market Cap: | US$231.700M |
September 25, 2025 September 24, 2025 September 15, 2025 August 14, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
